ACRV ACRV
Company Profile ↓Company Overview
ACRV (ACRV) is a publicly traded company listed on with a market capitalization of $51.90M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +23.31% |
| 6 Months: | -6.82% |
| 3 Months: | -21.15% |
| 1 Month: | -11.83% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.74 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 45.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.66M | 22.65M | 19.69M | 20.12M | 19.90M |
| Operating Income | - | - | -2.67M | -7.21M | -5.92M | -9.57M | -14.39M | -15.52M | -16.14M | -17.67M | -21.44M | -25.14M | - | -21.66M | -22.65M | -19.69M | -20.12M | -19.90M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -21.35M | -22.31M | -19.34M | -19.75M | -19.52M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -19.68M | -21.01M | -18.23M | -18.98M | -19.04M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -6.91M | -2.55M | -2.44M | -7.22M | -5.82M | -9.20M | -12.76M | -13.91M | -14.47M | -16.49M | -18.80M | -22.44M | - | -19.68M | -21.01M | -18.23M | -18.98M | -19.04M |
| Diluted EPS | - | - | -1.38 | -4.08 | -3.29 | -5.17 | -0.58 | -0.63 | -0.66 | -0.73 | -0.52 | -0.59 | -0.60 | -0.51 | -0.55 | -0.47 | - | -0.49 |
| R&D Expense | - | - | - | - | - | - | 9.76M | 10.52M | 10.27M | 11.47M | 15.03M | 18.86M | - | 15.41M | 16.18M | 13.65M | - | 15.17M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 32.66M | 67.10M | 89.20M | 84.11M |
| Operating Income | - | -32.66M | -67.10M | -89.20M | -84.11M |
| EBITDA | - | -32.29M | -66.57M | -88.19M | -82.76M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -31.17M | -60.39M | -80.56M | -77.91M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -31.17M | -60.39M | -80.56M | -77.91M |
| Diluted EPS | - | -7.56 | -2.74 | -2.38 | -2.02 |
| R&D Expense | - | 23.95M | 46.02M | 63.99M | 59.99M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 181.23M | 138.26M | 196.59M | 129.72M |
| Current Assets | - | - | 132.09M | 129.69M | 181.63M | 120.44M |
| Cash & Equivalents | - | - | 29.52M | 36.02M | 39.82M | 41.50M |
| Inventory | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Total Liabilities | - | - | 10.75M | 17.07M | 19.80M | 17.20M |
| Current Liabilities | - | - | 6.52M | 13.30M | 17.21M | 15.66M |
| Long Term Debt | - | - | - | - | - | - |
| Total Debt | - | - | 4.96M | 4.64M | 3.65M | 2.71M |
| Total Equity | -8.41M | - | 170.47M | 121.19M | 176.79M | 112.52M |
| Shares Outstanding | - | - | 21.92M | 22.52M | 31.23M | 31.65M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -30.12M | -42.64M | -65.67M | -63.66M |
| Investing Cash Flow | - | -141.68M | 50.72M | -51.77M | 66.10M |
| Financing Cash Flow | - | 101.71M | -1.55M | 121.03M | -749.00K |
| Capital Expenditure | - | -2.17M | -1.29M | -2.77M | -1.67M |
| Free Cash Flow | - | -32.28M | -43.93M | -68.44M | -65.33M |
| Net Change in Cash | - | -70.08M | 6.52M | 3.59M | 1.69M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -18.3% | -49.8% | -45.6% | -69.2% |
| ROCE % | - | -18.7% | -53.7% | -49.7% | -73.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ACRV
Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study
Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a year Oral weekly regimen (3 days on/4 days off) at 120 mg and 1…
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
Presentations feature mechanistic data on ACR-2316, a potential first-in-class, clinical WEE1/PKMYT1 inhibitor, rationally designed with AP3 for potent single agent activity and superior therapeutic index Early clinical responses, including…
Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
WATERTOWN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its propriet…
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its propriet…
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms in second half 2026 The ACR-2316 Phase 1/…
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy of ACR-368 with Topoisomerase 1 (Topo 1) inhibition Data supports potential for frontline clini…
ACRV — Frequently Asked Questions
What is the current share price of ACRV?
As of 2026-08-05 17:25 PDT, ACRV trades at $1.64 on NASDAQ/NYSE. Its 52-week range is $1.23 to $3.01.
What is the market capitalisation of ACRV?
ACRV has a market capitalisation of $51.90M on NASDAQ/NYSE.
What is the P/E ratio of ACRV?
ACRV trades at a trailing price-to-earnings (P/E) ratio of -0.81. Its price-to-book (P/B) ratio is 0.46.
What is the return on equity (ROE) of ACRV?
ACRV has a return on equity (ROE) of -69.24%. Its return on capital employed (ROCE) is -73.75%.
Is ACRV a good stock to buy?
This page provides a data-driven analysis of ACRV, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.